Sheaff Brock Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-366	Closed	-$231K	–	564
2021 Q4	$231K	Buy	+366	New	+$225K	0.02%	454
2020 Q3	–	Sell	-390	Closed	-$243K	–	494
2020 Q2	$243K	Buy	+390	New	+$221K	0.02%	349
2017 Q4	–	Sell	-490	Closed	-$219K	–	562
2017 Q3	$219K	Sell	490 -150	-23%	-$71.4K	0.03%	453
2017 Q2	$314K	Sell	640 -110	-15%	-$48.1K	0.04%	375
2017 Q1	$291K	Buy	750 +10	+1%	+$3.71K	0.04%	403
2016 Q4	$272K	Sell	740 -280	-27%	-$106K	0.03%	437
2016 Q3	$410K	Buy	1,020 +35	+4%	+$14K	0.05%	298
2016 Q2	$344K	Hold	985	–	–	0.04%	343
2016 Q1	$355K	Buy	985 +150	+18%	+$61.8K	0.04%	348
2015 Q4	$453K	Buy	+835	New	+$452K	0.05%	332

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sheaff Brock Investment Advisors's REGN Position: Q1 2022 in Review

Sheaff Brock Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 366 shares — an estimated $231K sold.

Sheaff Brock Investment Advisors first reported a position in REGN in Q4 2015 and held it in 10 quarters. The position peaked at $453K in Q4 2015. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Sheaff Brock Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 366 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $231K.
Sheaff Brock Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Sheaff Brock Investment Advisors's Regeneron Pharmaceuticals position peaked at $453K in Q4 2015.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2022, filed 6 May 2022.